Gleevec's Latest Approval is for Pediatric Cancer
FRIDAY, Jan. 25 (HealthDay News) -- The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said Friday.
Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) progresses rapidly if left untreated. Gleevec, among a class of drugs called tyrosine kinase inhibitors, blocks proteins that promote development of cancer cells, the FDA said in a news release.
The most common side effects observed in pediatric testing included infection and a decrease in white blood cells and blood platelets.
Gleevec was first approved in 2001 to treat a form of chronic myeloid leukemia, and has since been approved to treat several other conditions. The drug is marketed by Novartis, based in East Hanover, N.J.
More information
To learn more about Gleevec, visit the U.S. National Cancer Institute.
-- Scott Roberts
Health News Copyright © 2013 HealthDay. All rights reserved.
Health News Today
Feed- Gene Discovery May Offer Breakthrough for Rare Leukemia 05/09/2013
- Scientists Pinpoint Most Major Genes Behind Deadly Blood Cancer 05/01/2013
- Water Pipe No Safer Than Cigarettes: Study 04/29/2013
- Soaring Prices Keep Leukemia Drugs From Patients, Experts Say 04/25/2013
- New Strategy Helps Young Lymphoma Patients Avoid Radiation Treatment 04/10/2013
- View More Leukemia News
Popular Features
Your Guide to Leukemia
Take a Personalized Health Test
How well are you controlling your symptoms?
What's Causing Your Symptoms?
15 Ways To Get Better Medicine
People who are actively involved in their medical care stay healthier, recover quicker when they're ill, and live longer, healthier lives.